Why lutetium-177-PSMA treatment sometimes may not help, and may even harm

Lu-177-PSMA usually improves survival

We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>

FDA approves enzalutamide for treatment of metastatic HSPC

Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …

“Adjuvant” similar to “early salvage” radiation outcome in meta-analysis

Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …

Data from the PROfound trial reported at ESMO

From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …

The first-line treatment of locally advanced prostate cancer (clinical stage T3)

Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …

Projecting risk for metastasis after radical prostatectomy

A new paper in Clinical Genitourinary Cancer has provided us with some more detailed information about risk for metastasis in men with recurrent prostate cancer after first-line surgery. … READ MORE …

The celebrity prostate cancer line-up … and what they actually say

What celebs say and don’t say about prostate cancer (if they say anything at all) has often been difficult for the average patient to understand — as are some of their apparent treatment decisions (if those are actually mentioned). … READ MORE …